May 8, 2020 / 11:29 AM / 17 days ago

BRIEF-Redhill Biopharma Receives FDA Approval For Covid-19 Clinical Study With Opaganib In The U.S.

May 8 (Reuters) - Redhill Biopharma:

* REDHILL BIOPHARMA RECEIVES FDA APPROVAL FOR COVID-19 CLINICAL STUDY WITH OPAGANIB IN THE U.S.

* REDHILL BIOPHARMA - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY AIMS TO ENROLL UP TO 40 PATIENTS WITH MODERATE-TO-SEVERE COVID-19 PNEUMONIA

* REDHILL BIOPHARMA -ALL 6 ANALYZED MODERATE-TO-SEVERE COVID-19 PATIENTS TREATED WITH OPAGANIB UNDER COMPASSIONATE USE IN ISRAEL WERE WEANED FROM OXYGEN Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below